Taro International Ltd

: Nucleoside & Guanosine Reverse Transcriptase Inhibitor. Lamivudine 300 mg, Abacavir 600 mg.
TABS.:30. The recomm. dosage for adult.& child. over the age of 12 wt. at least 40 kg, is one tab., once dly. See lit.
Indicated in antiretrovir. comb. ther. for the tmt. of (HIV) infect. in adult., adolesc. and child. weigh. at least 25 kg.
C/I: Hypersens.

 

Retinoids. Adapalene 1 mg (0.1%), Benzoyl Peroxide 25 mg (2.5%).
TOPICAL GEL:  30 g. For extern. use only.  Thin layer of gel evenly over acne (pimples) affected areas should be appl. once dly., at bdtme. on a clean dry skin.
Eyes, lips, nostrils contact should be avoid. See lit.
Cutaneous tmt. of acne vulgaris when comedones, papules and pustules are present.
C/I: Hypersens.
Women who are preg. or suspect. to be preg.

 

Anticoagulant, Direct Factor Xa Inhibitor. Apixaban 2.5 mg, 5 mg.
Prevention of VTE (VTEp): elective hip or knee replacement surgery The recommended dose of apixaban is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery. Treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily. For the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily. See full prescription info.
for 2.5 mg: For prevention of venous thrombotic events in adult patients following elective hip or knee replacement surgery. For prevention of stroke and embolism in adult patients with atrial fibrillation (of a nonvalvular source) and with at least one risk factor, such as prior stroke or transient ischemic attack, aged 75 years and above, hypertension, diabetes mellitus, symptomatic heart failure. For treatment of blood clots in the veins of the legs (deep-vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent recurrence of blood clots in these blood vessels.
for 5.0 mg:   For prevention of stroke and embolism in adult patients with atrial fibrillation (of a nonvalvular source) and with at least one risk factor, such as prior stroke or transient ischemic attack, aged 75 years and above, hypertension, diabetes mellitus, symptomatic heart failure. For treatment of blood clots in the veins of the legs (deep-vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism)
C/I:  Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. • Active clinically significant bleeding. • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk • Lesion or condition if considered a significant risk factor for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. • Concomitant treatment with any other anticoagulant agent e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etexilate etc.) except under specific circumstances of switching anticoagulant therapy when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation.

Proteasome Inhibitor. Bortezomib 3.5 mg.
VIAL (Pwdr. for sol. for inj.): 1×3.5 mg. Dosage should be ajust. individ. See lit.
Multiple Myeloma.
Mantle Cell Lymphoma: For the tmt. of pts/ with mantle cell lymphoma who have received at least one prior ther.
Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin & prednisone is indicated for the tmt. of adult pts. with previous. untreat. mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
C/I: Hypers. to bortezomib, boron or mannitol. Acute diffuse infiltrative pulmon. and pericard. dis. Intrathecal admin.

Endothelin Receptor Antagonist. Bosentan 62.5 mg, 125 mg.
FC Tab 56 X 62.5/125 mg
Pulmonary arterial hypertension:  In adult pts., initiate at a dose of 62.5 mg twice daily for 4 weeks and then incr. to maint. dose of 125 mg twice daily.
Systemic sclerosis with ongoing digital ulcer disease:  initiate at a dose of 62.5 mg twice daily for 4 weeks and then incr. to maint. dose of 125 mg twice daily. Clinical experience is limited to 6 months.
The ptt’s response to tmt. and need for contin. ther. should be re-evaluated on a regular basis. A careful benefit / risk assessm. should be made, taking into consideration the liver tox. of bosentan. There are no data on the safety and efficacy in pts. under the age of 18 years.
Primary pulmonary arterial HT or second. to scleroderma or other connective tissue disease. To reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer dis.
C/I: Hypersens./ Moder. to sev. hepatic impairm. i.e. Child-Pugh Class B or C
/Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT), greater than 3 times the upper limit of normal.
/ Concom. use of cyclosporine A
/ Pregn. Women of childbearing potent. who are not using reliable methods of contraception